NCT06007014 - Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 Diabetes | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

October 30, 2025

Study Completion Date

December 30, 2025

Conditions

Efficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM PatientsMetformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect128 Patients Were Randomly Assigned 1:1Metformin and Insulin Glargine Combined With Chiglitazar Sodium Tablets 48mg/ Day GroupMetformin and Insulin Glargine Combined With Placebo GroupInvestigatorInitiate TrialChanges in HbA1C From Baseline at 18 Weeks of Treatment

Interventions

DRUG

Chiglitazar sodium

tablets 48mg/ day administered for 18 weeks

DRUG

Chiglitazar placebo

tablets 48mg/ day administered for 18 weeks

Trial Locations (1)

510000

the First Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Yanbing Li

OTHER